Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis

BackgroundGliomas are highly aggressive, life-threatening tumors with poor prognosis, and remain a leading cause of mortality among brain cancers. Although the role of mitochondrial proteins in cancer has garnered increasing attention, their specific functions in the nervous system, particularly in...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanyu Ding, Lizhi Xiao, Xiaoling Zhou, Jiaxin Zhao, Jianli Ke, Huabao Cai, Mengyu Zhao, Cunzhi Wang, Tianhang Yu, Zhijie Zhao, Yucai Wang, Jiyuan Ke
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1581850/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850166301229580288
author Yanyu Ding
Yanyu Ding
Lizhi Xiao
Lizhi Xiao
Xiaoling Zhou
Xiaoling Zhou
Jiaxin Zhao
Jiaxin Zhao
Jianli Ke
Jianli Ke
Huabao Cai
Mengyu Zhao
Cunzhi Wang
Tianhang Yu
Zhijie Zhao
Yucai Wang
Yucai Wang
Yucai Wang
Jiyuan Ke
Jiyuan Ke
author_facet Yanyu Ding
Yanyu Ding
Lizhi Xiao
Lizhi Xiao
Xiaoling Zhou
Xiaoling Zhou
Jiaxin Zhao
Jiaxin Zhao
Jianli Ke
Jianli Ke
Huabao Cai
Mengyu Zhao
Cunzhi Wang
Tianhang Yu
Zhijie Zhao
Yucai Wang
Yucai Wang
Yucai Wang
Jiyuan Ke
Jiyuan Ke
author_sort Yanyu Ding
collection DOAJ
description BackgroundGliomas are highly aggressive, life-threatening tumors with poor prognosis, and remain a leading cause of mortality among brain cancers. Although the role of mitochondrial proteins in cancer has garnered increasing attention, their specific functions in the nervous system, particularly in gliomas, remain poorly understood.MethodsWe integrated single-cell RNA sequencing with cellular assays and flow cytometry to investigate the molecular characteristics and cellular interactions within glioblastoma subpopulations during tumor progression.ResultsSingle-cell RNA sequencing revealed several differentially expressed genes (DEGs) within glioblastoma subpopulations. Trajectory analysis identified CHCHD2P9 as a pivotal marker for the terminal subpopulation. Moreover, elevated expression of CHCHD2P9 was found to correlate with poorer clinical outcomes. Subsequent cellular experiments further explored the underlying mechanisms driving these observations.ConclusionsCHCHD2P9 is significantly overexpressed in glioma patients, and its differential expression plays a crucial role in regulating glioma cell proliferation and migration. A CHCHD2P9-based risk model holds promise as both a prognostic biomarker and a potential therapeutic target, providing novel insights into the pathogenesis of gliomas and opening avenues for personalized treatment strategies.
format Article
id doaj-art-c52a6408edce4502ba7677d85f7a54e8
institution OA Journals
issn 1664-3224
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-c52a6408edce4502ba7677d85f7a54e82025-08-20T02:21:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15818501581850Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosisYanyu Ding0Yanyu Ding1Lizhi Xiao2Lizhi Xiao3Xiaoling Zhou4Xiaoling Zhou5Jiaxin Zhao6Jiaxin Zhao7Jianli Ke8Jianli Ke9Huabao Cai10Mengyu Zhao11Cunzhi Wang12Tianhang Yu13Zhijie Zhao14Yucai Wang15Yucai Wang16Yucai Wang17Jiyuan Ke18Jiyuan Ke19Department of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, ChinaDepartment of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaThe Chinese Academy of Sciences (CAS) Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Immunology, School of Basic Medical Sciences, Center for Big Data and Population Health of Institute of Health and Medicine (IHM), Anhui Medical University, Hefei, ChinaInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei Economic and Technological Development Zone, Hefei, Anhui, ChinaBackgroundGliomas are highly aggressive, life-threatening tumors with poor prognosis, and remain a leading cause of mortality among brain cancers. Although the role of mitochondrial proteins in cancer has garnered increasing attention, their specific functions in the nervous system, particularly in gliomas, remain poorly understood.MethodsWe integrated single-cell RNA sequencing with cellular assays and flow cytometry to investigate the molecular characteristics and cellular interactions within glioblastoma subpopulations during tumor progression.ResultsSingle-cell RNA sequencing revealed several differentially expressed genes (DEGs) within glioblastoma subpopulations. Trajectory analysis identified CHCHD2P9 as a pivotal marker for the terminal subpopulation. Moreover, elevated expression of CHCHD2P9 was found to correlate with poorer clinical outcomes. Subsequent cellular experiments further explored the underlying mechanisms driving these observations.ConclusionsCHCHD2P9 is significantly overexpressed in glioma patients, and its differential expression plays a crucial role in regulating glioma cell proliferation and migration. A CHCHD2P9-based risk model holds promise as both a prognostic biomarker and a potential therapeutic target, providing novel insights into the pathogenesis of gliomas and opening avenues for personalized treatment strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1581850/fullglioblastomaCHCHD2P9diagnosisprognosiscentral nervous systemtumor microenvironment
spellingShingle Yanyu Ding
Yanyu Ding
Lizhi Xiao
Lizhi Xiao
Xiaoling Zhou
Xiaoling Zhou
Jiaxin Zhao
Jiaxin Zhao
Jianli Ke
Jianli Ke
Huabao Cai
Mengyu Zhao
Cunzhi Wang
Tianhang Yu
Zhijie Zhao
Yucai Wang
Yucai Wang
Yucai Wang
Jiyuan Ke
Jiyuan Ke
Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
Frontiers in Immunology
glioblastoma
CHCHD2P9
diagnosis
prognosis
central nervous system
tumor microenvironment
title Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
title_full Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
title_fullStr Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
title_full_unstemmed Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
title_short Molecular insights into glioblastoma progression: role of CHCHD2P9 in tumor heterogeneity and prognosis
title_sort molecular insights into glioblastoma progression role of chchd2p9 in tumor heterogeneity and prognosis
topic glioblastoma
CHCHD2P9
diagnosis
prognosis
central nervous system
tumor microenvironment
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1581850/full
work_keys_str_mv AT yanyuding molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT yanyuding molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT lizhixiao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT lizhixiao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT xiaolingzhou molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT xiaolingzhou molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jiaxinzhao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jiaxinzhao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jianlike molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jianlike molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT huabaocai molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT mengyuzhao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT cunzhiwang molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT tianhangyu molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT zhijiezhao molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT yucaiwang molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT yucaiwang molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT yucaiwang molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jiyuanke molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis
AT jiyuanke molecularinsightsintoglioblastomaprogressionroleofchchd2p9intumorheterogeneityandprognosis